Algernon Pharmaceuticals appoints Sandor Nardai as OI for Phase 2a DMT study

Algernon Pharmaceuticals (AGNPF)’ Algernon NeuroScience has appointed Dr. Sandor Nardai as the Principal Investigator for its upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Sandor Nardai is a cerebrovascular disease specialist with completed training and licences to practice interventional cardiology, neurology and neurointerventions. He is associate professor and the Head of the Department of Neurointervention at the Semmelweis University Center of Neurosurgery and Neurointervention in Budapest, Hungary – the country’s largest primary stroke center, serving a population of 3.5 million people.